Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares in the company, valued at approximately $4,606,723.73. The trade was a 16.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total transaction of $867,350.00.

Centessa Pharmaceuticals Price Performance

CNTA opened at $15.75 on Friday. The firm has a market cap of $2.08 billion, a P/E ratio of -10.29 and a beta of 1.54. The firm has a 50-day moving average of $16.47 and a 200 day moving average of $16.40. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its stake in shares of Centessa Pharmaceuticals by 279.2% during the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after acquiring an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC bought a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $20,994,000. Franklin Resources Inc. boosted its holdings in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in shares of Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on CNTA. Guggenheim restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Morgan Stanley reiterated an “overweight” rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.